Business Description
Zelira Therapeutics Ltd
NAICS : 212221
ISIN : AU000000ZLD1
Compare
Compare
Traded in other countries / regions
ZLD.AustraliaZLDAF.USAG1G.Germany IPO Date
2016-12-28Description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.04 | |||||
| Equity-to-Asset | -0.73 | |||||
| Debt-to-Equity | -0.74 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -0.35 | |||||
| Beneish M-Score | -5.92 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 26.1 | |||||
| 3-Year EPS without NRI Growth Rate | 28.7 | |||||
| 3-Year FCF Growth Rate | 20.5 | |||||
| 3-Year Book Growth Rate | -23.5 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 98.49 | |||||
| 9-Day RSI | 81.6 | |||||
| 14-Day RSI | 58.04 | |||||
| 6-1 Month Momentum % | -20.41 | |||||
| 12-1 Month Momentum % | -12.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.43 | |||||
| Quick Ratio | 0.15 | |||||
| Cash Ratio | 0.01 | |||||
| Days Inventory | 1964.47 | |||||
| Days Sales Outstanding | 634.06 | |||||
| Days Payable | 3119.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -27.1 | |||||
| Shareholder Yield % | -29.57 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -2.87 | |||||
| Operating Margin % | -2570.61 | |||||
| Net Margin % | -13057.71 | |||||
| FCF Margin % | -1927.81 | |||||
| ROE % | -177.38 | |||||
| ROA % | -151.53 | |||||
| ROIC % | -31.82 | |||||
| ROC (Joel Greenblatt) % | -5790 | |||||
| ROCE % | -174.68 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 25.77 | |||||
| EV-to-EBIT | -0.25 | |||||
| EV-to-EBITDA | -0.26 | |||||
| EV-to-Revenue | 33.2 | |||||
| EV-to-FCF | -1.72 | |||||
| Earnings Yield (Greenblatt) % | -400 | |||||
| FCF Yield % | -70.71 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ZLDAF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zelira Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.187 | ||
| EPS (TTM) ($) | -2.167 | ||
| Beta | 2.66 | ||
| Volatility % | 71.59 | ||
| 14-Day RSI | 58.04 | ||
| 14-Day ATR ($) | 0.001648 | ||
| 20-Day SMA ($) | 0.483 | ||
| 12-1 Month Momentum % | -12.73 | ||
| 52-Week Range ($) | 0.4704 - 1.65 | ||
| Shares Outstanding (Mil) | 11.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zelira Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zelira Therapeutics Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zelira Therapeutics Ltd Frequently Asked Questions
What is Zelira Therapeutics Ltd(ZLDAF)'s stock price today?
The current price of ZLDAF is $0.50. The 52 week high of ZLDAF is $1.65 and 52 week low is $0.47.
When is next earnings date of Zelira Therapeutics Ltd(ZLDAF)?
The next earnings date of Zelira Therapeutics Ltd(ZLDAF) is .
Does Zelira Therapeutics Ltd(ZLDAF) pay dividends? If so, how much?
Zelira Therapeutics Ltd(ZLDAF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers